指南与共识呼吸衰竭与机械通气儿科与产科急症

儿科呼吸系统疾病吸入性黏液活性药物专家推荐:印度视角

Expert group recommendation on inhaled mucoactive drugs in pediatric respiratory diseases: an Indian perspective.
指南 / 共识 · Front Pediatr · 2023-12-04
一句话结论专家组认为吸入性黏液活性药物可改善囊性纤维化患儿黏液纤毛清除,对非囊性纤维化支气管扩张、急性毛细支气管炎和原发性纤毛运动障碍可能有益。

针对印度儿科呼吸系统疾病吸入性黏液活性药物使用缺乏指南的现状,由九名儿科呼吸专家和一名微生物学专家组成的小组通过电子检索PubMed/MEDLINE、Cochrane Library、Scopus和Embase数据库,围绕12个问题召开圆桌会议形成共识,并对证据水平和推荐等级进行分级。结论指出,高渗盐水、甘露醇干粉和阿法链道酶可增强囊性纤维化患儿的黏液纤毛清除;专家认为高渗盐水对非囊性纤维化支气管扩张、急性毛细支气管炎和原发性纤毛运动障碍可能有益;现有证据不足以支持在哮喘、急性喘息、气管软化、气管支气管软化和食管闭锁伴气管食管瘘中使用吸入性黏液活性药物。

要点

  • 吸入性高渗盐水、甘露醇干粉和阿法链道酶可增强囊性纤维化患儿的黏液纤毛清除。
  • 专家认为高渗盐水对非囊性纤维化支气管扩张、急性毛细支气管炎和原发性纤毛运动障碍可能有益。
  • 现有证据不足以支持在哮喘、急性喘息、气管软化、气管支气管软化和食管闭锁伴气管食管瘘中使用吸入性黏液活性药物。
  • 该共识由九名儿科呼吸专家和一名微生物学专家组成的小组制定,围绕12个问题形成。

适用人群与场景

  • 儿科呼吸系统疾病患者,包括囊性纤维化、非囊性纤维化支气管扩张、急性喘息、哮喘、原发性纤毛运动障碍、危重症、机械通气、气管软化、气管支气管软化、食管闭锁伴气管食管瘘、急性毛细支气管炎等。

研究设计与关键结果

  • 专家组由九名在儿科呼吸系统疾病方面有丰富经验的专家和一名微生物学专家组成,通过电子检索PubMed/MEDLINE、Cochrane Library、Scopus和Embase数据库,围绕12个问题召开圆桌会议达成共识,并对证据水平和推荐等级进行分级。
  • 吸入性黏液活性药物(高渗盐水、甘露醇干粉和阿法链道酶)可增强囊性纤维化患儿的黏液纤毛清除。
  • 专家认为高渗盐水对非囊性纤维化支气管扩张、急性毛细支气管炎和原发性纤毛运动障碍可能有益。
  • 现有证据不足以支持在哮喘、急性喘息、气管软化、气管支气管软化和食管闭锁伴气管食管瘘中使用吸入性黏液活性药物。

证据类型、等级与局限

  • 证据类型:专家共识(指南)。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 对于囊性纤维化患儿,可考虑使用吸入性高渗盐水、甘露醇干粉或阿法链道酶以增强黏液纤毛清除(根据原文结论)。
  • 对于非囊性纤维化支气管扩张、急性毛细支气管炎和原发性纤毛运动障碍患儿,专家认为高渗盐水可能有益(根据原文结论)。
  • 对于哮喘、急性喘息、气管软化、气管支气管软化和食管闭锁伴气管食管瘘患儿,现有证据不足以支持使用吸入性黏液活性药物(根据原文结论)。

指南或共识出处

  • Expert group recommendation on inhaled mucoactive drugs in pediatric respiratory diseases: an Indian perspective(Front Pediatr)。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

BACKGROUND: Currently, there are no guidelines or consensus statements about the usage of inhaled mucoactive drugs in pediatric respiratory disease conditions from an Indian perspective.

OBJECTIVE: To develop a practical consensus document to help pediatricians in clinical decision-making when choosing an appropriate mucoactive drug for the management of specific respiratory disease conditions.

METHODS: A committee of nine experts with significant experience in pediatric respiratory disease conditions and a microbiological expert constituted the panel. An electronic search of the PubMed/MEDLINE, Cochrane Library, Scopus, and Embase databases was undertaken to identify relevant articles. Various combinations of keywords such as inhaled, nebulized, mucoactive, mucolytic, mucokinetic, expectorants, mucoregulators, mucociliary clearance, respiratory disorders, pediatric, cystic fibrosis (CF), non-CF bronchiectasis, acute wheezing, asthma, primary ciliary dyskinesia (PCD), critically ill, mechanical ventilation, tracheomalacia, tracheobronchomalacia, esophageal atresia (EA), tracheoesophageal fistula (TEF), acute bronchiolitis, sputum induction, guideline, and management were used. Twelve questions were drafted for discussion. A roundtable meeting of experts was conducted to arrive at a consensus. The level of evidence and class of recommendation were weighed and graded.

CONCLUSIONS: Inhaled mucoactive drugs (hypertonic saline, dry powder mannitol, and dornase alfa) can enhance mucociliary clearance in children with CF. Experts opined that hypertonic saline could be beneficial in non-CF bronchiectasis, acute bronchiolitis, and PCD. The current state of evidence is inadequate to support the use of inhaled mucoactive drugs in asthma, acute wheezing, tracheomalacia, tracheobronchomalacia, and EA with TEF.

来源:Front Pediatr,查看原文。版权归原作者所有。

参考来源

  1. Singh M, Varkki S, Kinimi I, et al. Expert group recommendation on inhaled mucoactive drugs in pediatric respiratory diseases: an Indian perspective. Front Pediatr. 2023. PMID: 38111626. doi:10.3389/fped.2023.1322360

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。